Kazia Therapeutics (KZIA) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Kazia Therapeutics (KZIA) over the past year, gaining 40.0% versus a gain of 24.4%. Over five years, PDSB leads with a -88.8% price change compared with -98.3% for KZIA. Kazia Therapeutics is the larger company by market cap ($102.0 million vs $100.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | PDSB |
|---|---|---|
| Share price | $8.93 | $1.38 |
| Market cap | $102.04M | $100.01M |
| 1-day change | +1.25% | +35.29% |
| YTD return | +29.61% | +79.22% |
| 1-year return | +24.37% | +39.96% |
| 5-year return | -98.30% | -88.81% |
| EPS (TTM) | $-6.85 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $1.55 |
| 52-week low | $4.86 | $0.195 |
| Distance from 52-week high | -48.68% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +216.46% | +262.32% |
| Average volume | 262.41K | 23.24M |
| Shares outstanding | 11.43M | 72.47M |
| Employees | 6 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed KZIA by 15.6 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
KZIA vs PDSB FAQ
Which is bigger, Kazia Therapeutics or PDS Biotechnology?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $102.04M compared with $100.01M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, KZIA or PDSB?
PDSB returned +39.96% over the past 12 months, compared with +24.37% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.